MINT-PRAVASTATIN TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

PRAVASTATIN SODIUM

זמין מ:

MINT PHARMACEUTICALS INC

קוד ATC:

C10AA03

INN (שם בינלאומי):

PRAVASTATIN

כמות:

10MG

טופס פרצבטיות:

TABLET

הרכב:

PRAVASTATIN SODIUM 10MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

30/100

סוג מרשם:

Prescription

איזור תרפויטי:

HMG-COA REDUCTASE INHIBITORS

leaflet_short:

Active ingredient group (AIG) number: 0122563001; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2021-02-09

מאפייני מוצר

Page 1 of 39
PRODUCT MONOGRAPH
Pr
MINT-PRAVASTATIN
Pravastatin Sodium Tablets, USP
10 mg, 20 mg and 40 mg
Lipid Metabolism Regulator
Mint Pharmaceuticals Inc.,
6575 Davand Drive
Mississauga, ON
L5T 2M3
Date of Preparation:
MAR 08, 2024
Control# 283801
Page 2 of 39
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................
3
CONTRAINDICATIONS
..........................................................................................................................
5
WARNINGS AND PRECAUTIONS
........................................................................................................
5
ADVERSE REACTIONS
........................................................................................................................
11
DRUG INTERACTIONS
........................................................................................................................
15
DOSAGE AND ADMINISTRATION
....................................................................................................
17
OVERDOSAGE
.......................................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................
19
STORAGE AND STABILITY
................................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................................
21
PART II: SCIENTIFIC INFORMATION
...................................................................................................
22
PHARMACEUTICAL INFORMATION
...............